N/A
Completed N=601
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)
Hepatitis C, Chronic · Hepacivirus
Source: ClinicalTrials.gov NCT00704522 ↗
Enrolled (actual)
601
Serious AEs
3.4%
Results posted
May 2010
Primary outcomePrimary: Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program — 298; 75 Participants
Summary
Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron pen and Rebetol according to label and the patient assistance program. This study will be compared to similar studies from other clinics using various patient support programs for the purpose of designing future comparative phase IV studies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program |
298; 75 | — |
| PRIMARY Average Length of Treatment With PegIntron/Rebetol |
28.8; 27.3 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients with hepatitis C
Exclusion Criteria
- According to the products' labeling (refer to Warnings, contraindications, and safety sections).
Data sourced from ClinicalTrials.gov (NCT00704522). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.